Clinical Trials Browser

Phase 1/2 × Immunotherapy × 30 days × Clear all

NCT07522411 2026-04-13

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

Phase 1/2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular